WALTHAM, Mass., July 26, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its second quarter 2018 financial results will be released on Thursday, August 2, 2018 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update… More

Transaction Underscores AMAG’s Focus on Clinical Development and Commercialization of Pharmaceuticals Company Intends to Use the Majority of Proceeds to Pay off High-Yield Debt WALTHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has entered into a definitive agreement to divest Cord Blood Registry (CBR®) to GI Partners, a private… More

WALTHAM, Mass. and WHITE PLAINS, N.Y., June 11, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) and March of Dimes today announced a strategic corporate partnership focused on a shared commitment to improve maternal health and birth outcomes, as well as to reduce health inequities. Through the partnership, AMAG will participate in the March of Dimes Prematurity Campaign Collaborative… More

WALTHAM, Mass., June 04, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bremelanotide, a first-in-class melanocortin 4 receptor agonist designed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The Prescription Drug User Fee… More

WALTHAM, Mass., May 29, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in the Jefferies 2018 Healthcare Conference on Tuesday, June 5th  at 3:30 p.m. ET. To access the live webcast, please visit the Investors section of the company’s website at amagpharmadev.wpengine.com. A replay of the event will be archived… More

WALTHAM, Mass., May 09, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today commended the recent action taken by the Centers for Medicare and Medicaid Services (CMS) to clarify statutory intent of section §1860D-2(e)(2)(A) of the Social Security Act, stating that drugs for the treatment of moderate to severe dyspareunia (pain during sexual intercourse), a symptom… More

Strong first quarter execution with two FDA approvals and submission of a new drug application Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) —  AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for the quarter ended March 31, 2018, provided a business update, and increased its full… More

WALTHAM, Mass., May 02, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of J. Alan Butcher as executive vice president and chief business officer effective immediately. He reports to William Heiden, president and chief executive officer. In his role at AMAG, Mr. Butcher is responsible for leading the company’s overall business… More

WALTHAM, Mass., April 27, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Deutsche Bank Annual Health Care ConferenceTuesday, May 8, 2018 at 8:40 a.m. ET Location: Boston, MA Bank of America Merrill Lynch Health Care ConferenceTuesday, May 15, 2018 at 4:20 p.m. PT… More

WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update… More